October 31, 2018 / 6:34 AM / 21 days ago

Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS, Oct 31 (Reuters) - Sanofi narrowed its 2018 profit target for the second time this year after it posted higher-than-expected third-quarter profits, helped by robust sales growth at its key vaccines unit and its rare diseases Genzyme division.

Third-quarter business net income was up 10.3 percent at constant exchange rates to 2.3 billion euros ($2.61 billion)while revenues were up 6.3 percent to 9.4 billion.

Analysts polled by Reuters in partnership with Inquiry Financial had on average been expecting a business net income of 2.14 billion euros on revenues of 9.3 billion.

$1 = 0.8818 euros Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below